You are here

Justice News

Department of Justice
U.S. Attorney’s Office
Western District of Pennsylvania

FOR IMMEDIATE RELEASE
Tuesday, October 16, 2018

Medical Director for Bridgeville Suboxone Clinic Pleads Guilty to Unlawfully Distributing Controlled Substances

PITTSBURGH, PA - A resident of Wexford, Pa. pleaded guilty in federal court to charges of unlawfully distributing controlled substances, United States Attorney Scott W. Brady announced today.

Mark R. Foster, 71, pleaded guilty to three counts before United States District Judge Nora Barry Fischer.

In connection with the guilty plea, the court was advised that co-defendant Terry Brown owned and operated Cherry Way, a Suboxone clinic, located in Bridgeville, PA, and Foster was a medical director at Cherry Way. Brown and Foster conspired together to create and submit unlawful prescriptions for Suboxone, Adderall and Percocet, and then unlawfully dispensed those controlled substances to Brown and others.

Judge Fischer scheduled sentencing for March 14, 2019 at 11 a.m. The law provides for a total sentence of 50 years in prison, a fine of $2,500,000, or both. Under the Federal Sentencing Guidelines, the actual sentence imposed is based upon the seriousness of the offenses and the prior criminal history, if any, of the defendant.

Assistant United States Attorney Robert S. Cessar is prosecuting this case on behalf of the government.

This investigation was conducted by the Western Pennsylvania Opioid Fraud and Abuse Detection Unit, which combines personnel and resources from the following agencies to combat the growing prescription opioid epidemic: Federal Bureau of Investigation, U.S. Health and Human Services – Office of Inspector General, Drug Enforcement Administration, Internal Revenue Service-Criminal Investigations, Pennsylvania Office of Attorney General -Medicaid Fraud Control Unit, United States Postal Inspection Service, U.S. Attorney’s Office – Criminal Division, Civil Division and Asset Forfeiture Unit, Department of Veterans Affairs-Office of Inspector General, Food and Drug Administration-Office of Criminal Investigations and the Pennsylvania Bureau of Licensing.

Topic(s): 
Opioids
Prescription Drugs
Updated October 16, 2018